HGPI convened the Second Forum “The Introduction of Cost-Effectiveness Assessment, Its Impact, and Compatibility with Other Systems” on September 13, 2018.

Based on the issues raised at the preparatory meeting “Rebalancing Healthcare Systems: Innovation and Sustainability Series – Issues Identified from the Trial Introduction of Cost-Effectiveness Assessment” held on May 31, we identified three key themes (technical issues, issues for institutionalization, and public understanding) to be discussed in FY2018 and have been conducting a series of forums.

 

 

In this meeting, a roundtable discussion on HTA implementation was held with experts from industry, government, academia, and civil society. The discussions included policy functions required for the future implementation of Cost-Effectiveness Assessment, as well as its impact on the current healthcare and drug pricing systems. 

The next forum is scheduled as follows:

• The Third Forum (November): Public Understanding 

        Increasing Public Awareness and Understanding on the Impacts and Benefits of Cost-Effectiveness Assessment  

 

Organizer: HGPI

Participants: Policymakers, representatives from the government, academia and private sectors 

 

Opening (Explanatory introduction)

• Ryoji Noritake (President, HGPI)

Roundtable Discussions “The Introduction of Cost-Effectiveness Assessment, Its Impact, and Compatibility with Other Systems”

Roundtable Speakers (Titles omitted, in Japanese syllabary order)

• Shunya Ikeda (Professor, Graduate School of Medicine/Public Health, International University of Health and Welfare)
• Yoshie Onishi (Director, Japan Operations, Creativ-Ceutical K.K.)
• Kosuke Kato (Managing Director, Edwards Lifesciences Limited)
• Isao Kamae (Project Professor, Graduate School of Public Policy, the University of Tokyo).
• Keiji Kono (Senior Vice President, Global Health Policy, External Affairs, Chugai Pharmaceutical Co., Ltd.)
• Shigekazu Komoto (Planning Officer, Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare (MHLW))
• Naokazu Saito (Chief, Policy Intelligence Division, Integrated Market Access Department, Janssen Pharmaceutical K.K.)
• Hiroyuki Sakamaki (Professor, School of Management, Tokyo University of Science)
• Naomi Sakurai (President, Cancer Solutions Co., Ltd.)
• Tomoyuki Takura (Project Professor, Department of Healthcare Economics and Health Policy, Graduate School of Medicine and Faculty of Medicine, the University of Tokyo)
• Toshio Nagase (Director, Government Affairs, Gilead Science K.K.)
• Hiroshi Nakamura (Professor, Graduate School of Business Administration, Keio University)
• Yoshiyuki Majima (President, Pancreatic Cancer Action Network Japan)

Moderator

• Joji Sugawara (Associate, HGPI)

 

Since 2016, HGPI has conducted a series of expert meetings entitled “Rebalancing Healthcare Systems: Innovation and Sustainability” to facilitate open discussions on HTA. Throughout these meetings, we have worked to identify the issues and to provide policy recommendations. For the past activities, please refer to the “Activity Report – Special Edition on Innovation and Sustainability” (attached below).